Anti-Nausea Based Drug Reduces Alzheimer`s Astrocytes In Mice
18 Sep 2024 //
FIERCE BIOTECH
Nanoform, PlusVitech Partner To Repurpose Aprepitant For Lung Cancer
09 Apr 2024 //
PR NEWSWIRE
Heron scores FDA for Aponvie, alternative to pills for postoperative nausea
20 Sep 2022 //
FIERCEPHARMA
FDA Confirms Paragraph IV Patent Litigation for Aprepitant
13 Jun 2022 //
FDA
Heron Submits HTX-019 NDA for Prevention of Postoperative Nausea and Vomiting
18 Nov 2021 //
PRNEWSWIRE
Torrent Pharms Generic Aprepitant Receives Approval in US
24 Oct 2020 //
FDA
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI®
16 Jul 2020 //
PRNEWSWIRE
Heron Announces FDA Approval of sNDA to Expand CINVANTI® Label for IV Push
26 Feb 2019 //
PR NEWSWIRE
Enforcement Report - Week of December 26, 2018
26 Dec 2018 //
FDA
Glenmark Pharm’s Generic Aprepitant Receives Approval In US
13 Oct 2017 //
FDA
Facing off rivals, Merck looks to expand CINV label on positive PhIII Emend study
29 Jun 2015 //
FIERCE BIOTECH
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
02 May 2015 //
FIERCE PHARMA MFG